


RECEIVED

NOV 08 2001

NOV 05 2001

RECEIVED



Please type a plus sign (+) inside this box

Copy #9

Approved for use through 10/31/2002. OMB 0654-0045  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/580,015
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Group Art Unit	1641
Examiner Name	Unassigned.
Attorney Docket Number	15270J-004750US

I hereby appoint:

☒ Practitioners at Customer Number

20350

 Place Customer  
 Number Bar Code  
 Label here

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number

☐ Firm or  
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

## SIGNATURE of Applicant or Assignee of Record

Name Neuralab Limited, by: Kevin Insley, Vice President

Signature

Date

AUGUST 31, 2001

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3167760 v1

 RECEIVED  
 SEP 26 2001  
 TC 1700

RECEIVED


NOV 08 2001

NOV 05 2001

RECEIVED

TECH CENTER 16002900

Please type a plus sign (+) inside this box

PTO/SB/81 (02-01)  
Approved for use on page 1 of 1, 2001, 01/03/95/04/96U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**POWER OF ATTORNEY OR  
AUTHORIZATION OF AGENT**

<b>Application Number</b>	09/580,015
<b>Filing Date</b>	May 26, 2000
<b>First Named Inventor</b>	Dale B. Schenk
<b>Title</b>	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
<b>Group Art Unit</b>	1641
<b>Examiner Name</b>	Unassigned.
<b>Attorney Docket Number</b>	15270J-004750US

I hereby appoint:

☐ Practitioners at Customer Number 

OR

☒ Practitioner(s) named below:Place Customer  
Number Bar Code  
Label here

Name	Registration Number
Nina M. Ashton	37,273
Jean M. Duvall	32,731
Lisabeth F. Murphy	31,547

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number ☐ Firm or  
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

**SIGNATURE of Applicant or Assignee of Record**

Name	Neuralab Limited, by: Kevin Insley, Vice President
Signature	
Date	August 31, 2001


NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3167776 v1

RECEIVED  
SEP 26 2001  
TC 1700



RECEIVED  
NOV 05 2001

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schenk  
Application No./Patent No.: 09/580,015 Filed/Issue Date: May 26, 2000  
Entitled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE  
Neuralab Limited, a corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Dale B. Schenk To : Elan Pharmaceuticals, Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0648, or for which a copy thereof is attached.

2. From: Elan Pharmaceuticals, Inc. To : Neuralab Limited  
The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0488, or for which a copy thereof is attached.

3. From:        To :         
The document was recorded in the United States Patent and Trademark Office at Reel       , Frame       , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.  
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

September 7, 2001  
Date

[Signature]  
Signature  
Kevin Insley  
Typed or printed name  
Vice President  
Title

RECEIVED  
SEP 26 2001  
TC 1700

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.